Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Callisto Pharmaceuticals has completed enrollment for its Phase II clinical trial of atiprimod to treat low to intermediate grade neuroendocrine carcinoma or advanced carcinoid cancer ahead of schedule.
Subscribe to our email newsletter
The trial, designed to enroll 40 patients, presently has patients enrolled at seven clinical sites in the US and was closed to further enrollment with the addition of the 40th patient.
Dr Gary Jacob, CEO, said: “We are pleased with the tremendous pace of enrollment that we experienced. We have patients who have now been on our drug for as long as 11 months, and we expect that by next year the bulk of patients will have been treated for six months or more on our drug. We anticipate at that time releasing interim data from the trial as well as planning for a meeting with FDA on the design of a registration trial.”
The primary objective of the Phase II clinical trial was to evaluate efficacy of Atiprimod in patients with low to intermediate grade neuroendocrine carcinoma who have metastatic or unresectable cancer and who have progression of their disease despite standard therapy (octreotide).